

## Revista Clínica de Periodoncia, Implantología y Rehabilitación Oral

### PROSPECTIVE STUDY OF THE AESTHETIC EFFECT OF BOTULINUM TOXIN A WHEN INJECTED INTO THE MUSCLES OF FACIAL EXPRESSION

|                               |   |
|-------------------------------|---|
| Journal:                      | <i>International Journal of Interdisciplinary Dentistry</i>   |
| Manuscript ID                 | REVISTA-2021-0004.R1  |
| Manuscript Type:              | Original Article  |
| Date Submitted by the Author: | 25-Mar-2021   |
| Complete List of Authors:     | Corrêa de Lima, Maristela; Universidade Estadual de Campinas Faculdade de Odontologia de Piracicaba,<br>Rizzatti Barbosa, Célia ; Universidade Estadual de Campinas Faculdade de Odontologia de Piracicaba<br>Duarte Gavião, Maria ; Universidade Estadual de Campinas Faculdade de Odontologia de Piracicaba<br>Ferreira Caria, Paulo ; Universidade Estadual de Campinas Faculdade de Odontologia de Piracicaba |
| Keywords:                     | Botulinum Toxin, Muscles of Expression, Gummy smile   |
|                               |   |

SCHOLARONE™  
Manuscripts

## PROSPECTIVE STUDY OF THE AESTHETIC EFFECT OF BOTULINUM TOXIN A WHEN INJECTED INTO THE MUSCLES OF FACIAL EXPRESSION

### ABSTRACT

Botulinum neurotoxin A (BoNT-A) causes an anticholinergic effect on neuronal fibers, which control muscle contraction and autonomic disorders. Thus, it has been widely used in facial aesthetics, decreasing the action of motor muscles and consequent wrinkles. This preliminary study evaluated the effect of BoNT-A in 77 patients, the treatment satisfaction index was defined in percentage (from 0% to 100%). The evaluation was carried out on 15th, 30th, 60th, 90th, and 180th days after BoNT. The data were analyzed using the Friedman, Student t, Mann-Whitney test with  $t$  ( $\alpha=0.05$ ). The results showed that at 15th and 30th days the scores were similar in all muscles with high level of satisfaction and until 90th days the scores decreased significantly for Corrugator supercillii 79.38%, Occipitofrontalis 71.46%, Orbicularis oculi 70.43%; but the satisfaction was good. At 180 days, there was a drop in effectiveness in all treated muscles since the scores decreased significantly, showing low satisfaction by the participants. This study demonstrated that the BoNT-A had attested satisfaction effect by participants for up to 90th days, but at 180th days the satisfaction was low. In the comparative analyzes between women under 40 and over 40 years of age, there was no significant differences.

**Keywords:** Botulinum Toxin, Muscles of Expression, Facial Aesthetic, Gummy smile.

## INTRODUCTION

Botulinum neurotoxin A (BoNT-A) is a product derived from the anaerobic bacterium *Clostridium botulinum*<sup>(1)</sup>. At low concentrations, BoNT-A enters the nerve endings, cleaving and inactivating the synaptosomal associated proteins 25 (SNAP-25) that are essential for the acetylcholine release, a neurotransmitter that acts on muscle contraction<sup>(2,3)</sup>. By temporarily reducing muscular contraction, BoNT-A prevents the formation of lines and rhytids. It also decreases the hyperactive muscle behavior. This aspect composes BoNT-A as a good option for facial aesthetic rejuvenation. BoNT-A is currently the most used material to reduce hyperkinetic facial lines, with techniques that injects this toxin into the muscles of facial expression<sup>(4)</sup>.

The duration of the BoNT-A effect is one of the main determinants of efficacy in an aesthetic treatment. BTX-A duration and efficacy depends on several factors, most of them can be controlled by the professional in order to obtain better results. Factors such as dosage, patient's metabolism, anatomical characteristics of the treated muscle, point and angle of injection, dilution techniques, and injection protocols may affect the duration of the BoNT-A effect<sup>(5)</sup>. Although the molecular mechanism underlying the duration of BoNT-A remains unknown, the toxin remains in the nerve terminal for months<sup>(6)</sup> and this aspect may determine the duration of its effect<sup>(7)</sup>.

The clinical effects of BoNT-A can last for 30 days up to 6 months<sup>(8)</sup>. However, data available in the literature regarding the efficacy and duration of BoNT-A effects on the muscles of facial expression are still controversial, and they do not address experimental criteria that define its usage protocol, especially

1  
2  
3 regarding to the patient's satisfaction as a function of the duration of action<sup>(9)</sup>.  
4  
5 Thus, this study estimated the patient satisfaction index in relation to the aesthetic  
6  
7 effect of BoNT-A as a function of its duration of action. [Furthermore, the possible](#)  
8  
9 [influence of age was also considered.](#)  
10  
11  
12  
13

## 14 **MATERIALS AND METHODS**

15  
16  
17  
18  
19 This preliminary prospective study was conducted in accordance with the  
20  
21 recommendations of the International Council for Harmonisation and the  
22  
23 principles of the Helsinki Declaration, under the approval by the Research Ethics  
24  
25 Committee of FOP/UNICAMP #60121116.1.0000.5418. All subjects that agreed  
26  
27 to participate in the study signed an informed consent form. This study consisted  
28  
29 of a prospective longitudinal clinical study conducted at the Clinic of  
30  
31 Specialization Courses in the Faculdade de Odontologia de Piracicaba – FOP, in  
32  
33 2016 and 2017.  
34  
35  
36

37  
38 Inclusion criteria were female patients, aged from 18 to 72 years (mean  
39  
40 age  $45 \pm 12.6$  years), presenting hyperkinetic facial lines from moderate to severe  
41  
42 indicated for correction by BoNT-A injection and/or gummy smile with muscular  
43  
44 origin, without any systemic alteration or contraindication to the use of botulinum  
45  
46 toxin. Pathologies that compromised the stomatognathic system, trigeminal  
47  
48 neuralgia, signs of ptosis, pathological decrease in muscle activity, facial  
49  
50 surgeries, aesthetic treatments in the past 12 months with botulinum neurotoxin  
51  
52 type A, patients who received plastic or orthognathic surgery were considered as  
53  
54 exclusion criteria. The final sample was composed of 77 patients.  
55  
56  
57  
58  
59  
60

1  
2  
3 The BoNT-A used was Botox® 100U (Allergan do Brasil, Guarulhos, São  
4 Paulo, Brazil), reconstituted in 2 mL of saline solution at 0.9%<sup>(2)</sup>. The injection  
5 procedure followed the manufacturer's instructions presented in the package  
6 insert. The injections were performed by a professional duly trained in these  
7 procedures. Facial regions, dosages, and injection techniques adopted were in  
8 agreement with the literature, as presented in Table 1.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 **(TABLE 1)**  
20  
21  
22  
23

24 Patient follow-up was carried out at 15, 30, 60, 90, and 180 days after  
25 BoNT-A injection. At each follow-up meeting, patients reported their self-  
26 perception to the outcome of the treatment. To measure the rate of satisfaction  
27 with the treatment in this period, patients issued their answers using a verbal  
28 analog scale measured in percentage numbers ranging from 0% to 100%, with  
29 0% representing the worst possible result, and 100%, the best possible result.  
30  
31  
32  
33  
34  
35  
36

37 The questions were formulated by the same rater who sought to inquire  
38 aspects related to the presence of wrinkles, quality of the skin regarding elasticity,  
39 softness, brightness, and firmness. At the end, patients indicated a percentage  
40 value for their satisfaction index. These parameters were observed equally  
41 throughout the evaluation period, considering the facial regions treated.  
42  
43  
44  
45  
46  
47  
48

49 After data collection, the information was compiled, inserted in tables, and  
50 submitted to statistical analysis. The analysis was performed by comparing linked  
51 sample data, that is, when the same individual is evaluated more than once. **First,**  
52 **the data from the total sample were compared between the evaluation days. In**  
53 **addition, two age groups were formed to verify for possible differences due to**  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 physiological reasons, the first consisting of women under 40 years of age and  
4  
5 the other of women over 40 years of age. Moreover, the scores were correlated  
6  
7 with age.  
8  
9

10 The Sigmaplot 14.0 software (Systat Software Inc., San Jose, CA, USA)  
11  
12 was used for all statistical analysis. A 0.05 alpha significance level was  
13  
14 considered. Friedman test for comparisons between evaluation days was  
15  
16 applied, as well as T-test and Mann-Whitney test for comparisons between  
17  
18 groups. Moreover, the correlation between age and patients' satisfaction scores  
19  
20 was calculated using Spearman coefficient.  
21  
22  
23  
24  
25

## 26 RESULTS

27  
28  
29  
30

31 According to the data analyses, significant differences occurred between  
32  
33 patients' satisfaction scores during the follow-up periods ( $p < 0.0001$ ), considering  
34  
35 each facial region treated. From 15 to 30 days post-operation, patients provided  
36  
37 very good percentages of treatment satisfaction for all facial regions, with values  
38  
39 above 90%. However, the effect decreased significantly at 60 days for the  
40  
41 treatments performed in the upper third of the Corrugator supercillii, Procerus,  
42  
43 Orbicularis oculi, and Occipitofrontalis muscles, although satisfaction scores  
44  
45 were still high. At that time, values of Occipitofrontalis, Levator labii superioris,  
46  
47 and Levator labii superioris alaeque nasi muscles were similar to 60 days. In the  
48  
49 period of 90 days, there was a significant decrease in the scores of Corrugator  
50  
51 supercillii, Occipitofrontalis and Orbicularis oculi in relation to 60 days, but the  
52  
53 values showed a good level of satisfaction. Moreover, at 90 days the scores for  
54  
55 Procerus, Levator labii superioris, and Levator labii superioris alaeque nasi  
56  
57  
58  
59  
60

1  
2  
3 muscles remained similar to the scores at 60 days, also demonstrating good  
4 satisfaction of the participants. At 180 days, the scores decreased significantly in  
5 relation to other evaluation days, demonstrating low satisfaction in relation to the  
6 clinical effects of BoNT-A for all muscles. The satisfaction scores are described  
7  
8  
9  
10  
11  
12 in table 2.

13  
14  
15  
16  
17 **(TABLE 2)**  
18  
19

20  
21 On comparing each evaluation day between the two age groups (Table 3),  
22 no statistical significant differences were found ( $p>0.05$ ). However, significant  
23 negative correlations were observed between age and patient satisfaction on day  
24 180 in *Corrugator supercillii* ( $r_s = -0.298$ ,  $p = 0.040$ ) and age and patient satisfaction  
25 on day 60 in *Occipitofrontalis* ( $r_s = -0.287$ ,  $p = 0.048$ ), meaning that the younger  
26 the age, the greater the satisfaction with the treatment in respective days and  
27 muscles. The correlations between other days and muscles were not significant.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 **(TABLE 3)**  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

The results of this study indicate that BoNT-A is a good option for aesthetic facial treatments, including gummy smile with high patients' satisfaction until 90 days after application, but at 180 days, the effect decreased, as demonstrated by low satisfaction scores.

Its mechanism of action is at peripheral cholinergic synapses; cleaves the protein associated with the synaptosome, 25 kDa (SNAP-25), which is present in the neuronal plasma membrane and inhibits the release of acetylcholine (ACh) at the neuromuscular junction, preventing muscle activity by chemical denervation. The BoNT-A acts on cholinergic neurons that is it inhibits the secretion of the neurotransmitter ACh from somatic and parasympathetic nerves, as well as some sympathetic nerves. In somatic nerves, the effects of paralysis and muscle atrophy by injections of BoNT-A used cosmetically to treat facial wrinkles with skin rejuvenation and to contour the lower part of the face, calf, neck and shoulders. In the parasympathetic nervous system, BoNT-A is also used to bypass the lower and mandibular lines using atrophy of the salivary glands<sup>(10)</sup>.

Thus, the predilection for females in this study occurs because of the anatomical muscle difference, which could lead to a difference in the self-perception scale (score from 0 to 100%). The anatomy is substantially different between sexes: the male skull is larger, with a different shape, it is heavier, and robust; whereas the female skull is lighter and more delicate. Men have wider forehead, with prominent superciliary arch, wider glabella, square orbit and quadrangular jaw, as well as larger skeleton and muscle structure – including

1  
2  
3 muscles of the facial expression. These anatomical differences should be  
4  
5 considered in any facial aesthetic study<sup>(11,12)</sup>.  
6

7  
8 The effect of BoNT-A in patients with gummy smile in this study was  
9  
10 effective for 60 days, with a significant decrease in effectiveness after 90 days,  
11  
12 but the scores showed good satisfaction. However, according to Mario Polo,  
13  
14 2008<sup>(13)</sup>; who treated 30 Hispanic individuals with gummy smile, injecting 2.5 U  
15  
16 into each muscle with BoNT-A, reported that the gingival display gradually  
17  
18 increased, from two weeks after injection to 24 weeks, but at 24 weeks, the  
19  
20 average gingival display had not yet returned to baseline values. In a 2018  
21  
22 systematic review and meta-analysis study, the authors state that a significant  
23  
24 effect of the treatment tends to be stable up to at least eight weeks of follow-up  
25  
26 and the effect can remain up to 12 weeks<sup>(14)</sup>. Another alternative for gummy smile  
27  
28 would be a surgical procedure, however, Gregnanin and Aulestia-Viera, 2017;  
29  
30 concluded in their study that the surgical procedure – besides being more  
31  
32 invasive – does not promote the result expected by the patient, and BoNT-A is a  
33  
34 fast and effective option for correcting the gummy smile, as long as the correct  
35  
36 amount of BoNT-A is respected according to the type of smile<sup>(15)</sup>.  
37  
38  
39  
40  
41

42 On the other hand, the longevity of BoNT-A in the occipitofrontalis muscle  
43  
44 is indicated in the literature to last on average from three to four months<sup>(16,17)</sup>. The  
45  
46 glabella region – comprising the procerus, corrugator supercilii, and orbicularis  
47  
48 oculi muscles. In a 2016 a study<sup>(18)</sup> composed of women aged from 18 to 64  
49  
50 years, with six months of follow-up, received a total dose of 50 U and two different  
51  
52 volumes of injection, and both the double volume of BoNT-A injection and the  
53  
54 marked volume of injection provide excellent efficacy, with early onset of the  
55  
56 effect and durability up to six months. Other studies indicate that the effect of  
57  
58  
59  
60

1  
2  
3 BoNT-A can be perceived two weeks after injection and it can last some three or  
4  
5 four months, rarely exceeding six months<sup>(19,20)</sup>. Also, other studies indicate that  
6  
7 the BoNT-A effect hardly lasts up to six months<sup>(21)</sup>. Thus, patients can expect from  
8  
9 the treatment with BoNT-A – for hyperkinetic facial lines – three months of  
10  
11 efficiency; effects after the fourth month, depend on the facial area, dose, and  
12  
13 formulation. Age, gender, and combined, repeated and previous treatments also  
14  
15 affect the efficacy of the procedure<sup>(22)</sup>. Nevertheless, in the present study a  
16  
17 negative significant correlation between age and the effectiveness of BoNT-A in  
18  
19 the occipitofrontalis muscle at 90 days was found, meaning that after three  
20  
21 months of application younger women were more satisfied with the treatment.  
22  
23  
24

25  
26 Age must also be taken into account, as aging causes flaccidity<sup>(23)</sup>. Thus,  
27  
28 comparing women under 40 and over 40, significant negative correlations  
29  
30 between age and patient satisfaction at 180 days were observed in *Corrugator*  
31  
32 *supercilii* ( $p = 0.040$ ) and at 60 days in *Occipitofrontalis* ( $p = 0.048$ ),  
33  
34 demonstrating that women under 40 have a better voluntary perception of these  
35  
36 muscles.  
37  
38  
39

40  
41 Therefore, anatomical changes, skin, soft and bone tissues, and soft tissue  
42  
43 descent contribute to the appearance of facial aging, in addition to this  
44  
45 physiological and anatomical perception. Bone changes with aging seem to  
46  
47 contribute to changes in facial aging, enlargement of the skull and frontal sinuses  
48  
49 can increase the superciliary arch. The lack of bone support can contribute to the  
50  
51 loss of volume under the eyebrow and descent of the eyebrow tissues. Thus, an  
52  
53 understanding of the anatomical changes of aging and the perception of these  
54  
55 changes can lead to more appropriate therapy<sup>(24)</sup>.  
56  
57  
58  
59  
60

1  
2  
3 Our study suggests that treatment with BoNT-A for aesthetic facial  
4 treatments was effective for up to 90 days, depending on the treated muscle, and  
5 at 180 days all muscles differed significantly from other days, showing low  
6 satisfaction with the treatment. In the comparative analyzes between women  
7 under 40 and over 40 years of age, there was no significant difference. However,  
8 the muscles Corrugator supercilii and Occipitofrontalis, showed a negative  
9 correlation in women under 40 years. Reinforcing, the importance of the patient  
10 to follow up with the clinician so that he can observe the correct dose in order to  
11 avoid overdosing or unnecessary recurrent injection.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23  
24 A comprehensive understanding of the aesthetic indications related to the  
25 BoNT-A cholinergic nervous system, in combination with associated  
26 physiological factors and conditions such as dosage, volume and dilution,  
27 distribution characteristics and injection techniques can influence the  
28 effectiveness of BoNT-A. In this way, more sophisticated treatment techniques  
29 and management policies to obtain the best effectiveness can be achieved,  
30 minimizing effects and helping to expand new advanced clinical indications for  
31 the cosmetic use of BoNT-A<sup>(12)</sup>.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Although this study demonstrated the effectiveness of BoNT-A, we have  
43 as limitation the method of satisfaction rate of the treatment reported by the  
44 patient, with the responses on a verbal analog scale, ranging from 0 to 100%,  
45 being a subjective evaluation method. However, further studies regarding optimal  
46 doses of BoNT-A are necessary, for each specific muscle, as well as for the time  
47 required for the next application, so that the patient receives a new dose only  
48 when necessary.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 However, our study contributes with its data compilation, its way of  
4 systematizing knowledge on the injection of BoNT-A for facial aesthetic  
5 treatments – including gummy smile – demonstrating the period of effectiveness  
6 of the BoNT-A based on the ideal minimum dosages in the muscles of facial  
7 expression.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

## 18 **CONCLUSION**

19  
20  
21 The BoNT-A was applied in muscles of facial expression, with attested  
22 satisfaction effect by participants for up to 90 days, but at 180 days the  
23 satisfaction was low. In the comparative analyzes between women under 40 and  
24 over 40 years of age, there was no significant differences.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**REFERENCES**

1. Barbero P, Busso M, Artusi CA, De Mercanti S, Tinivella M, Veltri A, et al. Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea. *J Vis Exp*. 2016 Nov 9;(117):54606. doi: 10.3791/54606.
2. Rizzatti-Barbosa CM, Albergaria-Barbosa JR. *Toxina botulínica em Odontologia*. Rio de Janeiro, Elsevier, 2017, 220p.
3. Baumann L, Dayan S, Connolly S, Silverberg N, Lei X, Drinkwater A, et al. Duration of Clinical Efficacy of OnabotulinumtoxinA in Crow's Feet Lines: Results from Two Multicenter, Randomized, Controlled Trials. *Dermatol Surg*. 2016 May;42(5):598-607. doi: 10.1097/DSS.0000000000000757.
4. Dover JS, Monheit G, Greener M, Pickett A. Botulinum Toxin in Aesthetic Medicine: Myths and Realities. *Dermatol Surg*. 2018 Feb;44(2):249-260. doi: 10.1097/DSS.0000000000001277.
5. Warren H, Welch K, Coquis-Knezek S. AbobotulinumtoxinA for Facial Rejuvenation: What Affects the Duration of Efficacy? *Plast Surg Nurs*. 2020 Jan/Mar;40(1):37-44. doi: 10.1097/PSN.0000000000000292.
6. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. *Nat Rev Microbiol*. 2014 Aug;12(8):535-49. doi: 10.1038/nrmicro3295
7. Hallett M. Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them. *Toxicon*. 2015 Dec 1;107(Pt A):64-7. doi: 10.1016/j.toxicon.2015.07.013.
8. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines:

1  
2  
3 efficacy and safety. *Dermatol Surg.* 2009 Dec;35(12):1893-901. doi:  
4  
5 10.1111/j.1524-4725.2009.01235.x.  
6

7  
8 **9.** Ogden S, Griffiths TW. A review of minimally invasive cosmetic  
9  
10 procedures. *Br J Dermatol.* 2008 Nov;159(5):1036-50. doi: 10.1111/j.1365-  
11  
12 2133.2008.08845.x.  
13

14  
15 **10.** Park, Mee Young, Ahn, Ki Young. Scientific review of the aesthetic uses  
16  
17 of botulinum toxin type A. *Archives of Craniofacial Surgery* 2021;22(1):1-10. DOI:  
18  
19 <https://doi.org/10.7181/acfs.2021.00003>  
20

21  
22 **11.** Keaney TC, Alster TS. Botulinum toxin in men: review of relevant anatomy  
23  
24 and clinical trial data. *Dermatol Surg.* 2013 Oct;39(10):1434-43. doi:  
25  
26 10.1111/dsu.12302.  
27

28  
29 **12.** Zimble MS, Kokoska MS, Thomas JR. Anatomy and pathophysiology of  
30  
31 facial aging. *Facial Plast Surg Clin North Am.* 2001 May;9(2):179-87, vii. PMID:  
32  
33 11457684.  
34

35  
36 **13.** Polo M. Botulinum toxin type A (Botox) for the neuromuscular correction  
37  
38 of excessive gingival display on smiling (gummy smile). *Am J Orthod Dentofacial*  
39  
40 *Orthop.* 2008 Feb;133(2):195-203. doi: 10.1016/j.ajodo.2007.04.033.  
41

42  
43 **14.** Chagas T A, Almeida N V, Lisboa C O, Ferreira D M T P, Mattos C T,  
44  
45 Mucha N J. Duration of effectiveness of Botulinum toxin type A in excessive  
46  
47 gingival display: a systematic review and meta-analysis. *Braz. oral res.*, 2018,  
48  
49 vol.32. <https://doi.org/10.1590/1807-3107bor-2018.vol32.0030>  
50

51  
52 **15.** Gregnanin Pedron Irineu, Aulestia-Viera Patricia Verónica. La toxina  
53  
54 botulínica como adyuvante en el tratamiento de la sonrisa gingival. *Rev. Clin.*  
55  
56 *Periodoncia Implantol. Rehabil. Oral*, 2017 Ago; 10( 2 ): 87-89. Disponible en:  
57  
58  
59  
60

1  
2  
3 [https://scielo.conicyt.cl/scielo.php?script=sci\\_arttext&pid=S0719-](https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0719-)

4  
5  
6 01072017000200087&lng=es. <http://dx.doi.org/10.1016/j.piro.2016.06.001>.

7  
8 **16.** Schlessinger J, Monheit G, Kane MA, Mendelsohn N. Time to onset of  
9  
10 response of abobotulinumtoxina in the treatment of glabellar lines: a subset  
11  
12 analysis of phase 3 clinical trials of a new botulinum toxin type A. *Dermatol Surg.*  
13  
14 2011 Oct;37(10):1434-42. doi: 10.1111/j.1524-4725.2011.02075.x.

15  
16  
17 **17.** Moy R, Maas C, Monheit G, Huber MB; Reloxin Investigational Group.  
18  
19 Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar  
20  
21 lines. *Arch Facial Plast Surg.* 2009;11(2):77-83. doi: 10.1001/archfacial.2009.5.

22  
23  
24 **18.** Punga AR, Alimohammadi M, Fagrell D, Nyberg F, Rees D, Wong C. A  
25  
26 Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection  
27  
28 Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines. *Dermatol Surg.*  
29  
30 2016 Aug;42(8):967-76. doi: 10.1097/DSS.0000000000000805.

31  
32  
33 **19.** Bhushan KS, Divya N, Shobha P. Botox: Its Illuminating Frontiers of  
34  
35 Dentistry. *International Journal of Pharmaceutical Sciences Review and*  
36  
37 *Research* 2016; 37(1):155-62.

38  
39  
40 **20.** Wickwar S, McBain H, Newman SP, Hirani SP, Hurt C, Dunlop N, et al.  
41  
42 Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin  
43  
44 treatment model for blepharospasm and hemifacial spasm compared to standard  
45  
46 care: study protocol for a randomised controlled trial. *Trials.* 2016 Mar  
47  
48 9;17(1):129. doi: 10.1186/s13063-016-1263-y.

49  
50  
51 **21.** Jaspers GW, Pijpe J, Jansma J. The use of botulinum toxin type A in  
52  
53 cosmetic facial procedures. *Int J Oral Maxillofac Surg.* 2011 Feb;40(2):127-33.  
54  
55 doi: 10.1016/j.ijom.2010.09.014.

1  
2  
3 **22.** Flynn TC. Botulinum toxin: examining duration of effect in facial aesthetic  
4 applications. *Am J Clin Dermatol.* 2010;11(3):183-99. doi: 10.2165/11530110-  
5  
6 000000000-00000.  
7

8  
9  
10 **23.** van den Bosch WA, Leenders I, Mulder P. Topographic anatomy of the  
11 eyelids, and the effects of sex and age. *Br J Ophthalmol.* 1999 Mar;83(3):347-52.  
12  
13 doi: 10.1136/bjo.83.3.347. PMID: 10365046  
14

15  
16 **24.** Branham G, Holds JB. Brow/Upper lid anatomy, aging and aesthetic  
17 analysis. *Facial Plast Surg Clin North Am.* 2015 May;23(2):117-27. doi:  
18  
19 10.1016/j.fsc.2015.01.001. PMID: 25921563.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1.** Description of the treated regions, muscles involved, BoNT-A dose, needle characteristics and injection angles.

|   | Reference to the Puncture Points  | Bont-A Dose (U)  | Tri-Bevel 32g Needle | Angle of Injection  |
|---|---|--|----------------------|---|
| <b>Gummy smile</b>                                  |   |  |                      |   |
| <i>Levator labii superioris</i> (n=15)              | Horizontal – 10mm from the <i>ala nasi</i> ; vertical – 30 mm of the labial commissure of mouth (Yonsei point) with the lips at rest  | 4 U in each point  | 6 mm                 | Perpendicular to the skin surface                                   |
| <i>Levator labii superioris alaeque nasi</i> (n=12) |   |  |                      |   |
| <b>Frontal rhytids</b>                              |   |  |                      |   |
| <i>Occipitofrontalis</i> (n=48)                     | Rhytids identified when expressing “fright.” V-shaped injection, based on the limited area between vertical lines passing through the distal of the iris and 10 mm above the eyebrows | Five to eight points within the security area, 2 U in each point | 4 mm                 | Perpendicular to the skin surface                                   |
| <b>Glabella</b>                                     |   |  |                      |   |
| <i>Procerus</i> (n=27)                              | Muscle identified when expressing “anger.”  | From 3 to 4 U in each point                                      | 6 mm                 | Perpendicular to the skin surface                                   |
| <i>Corrugator supercilii</i> (n=45)                 |   |  |                      |   |
| <b>Periorbital lines</b>                            |   |  |                      |   |
| <i>Orbicularis oculi</i> (n=46)                     | Muscle identified when expressing a “fake smile,” keeping 10 mm of distance from the lateral of the <i>rima palpebrarum</i> , above the upper margin of the zygomatic bone            | 1 U in each point  | 4 mm                 | 45° angle to the skin surface, towards the lateral side of the face |

**Table 2.** Satisfaction scores on the effects of the treatment with BoNT-A on the muscles of expression and number of patients who received the treatment, according to the evaluation periods. Values are expressed as Mean (standard deviation).

|   | Satisfaction scores (%) in the evaluation periods |                             |                             |                            |                            |
|---|---|-----------------------------|-----------------------------|----------------------------|----------------------------|
|   | 15 Days   | 30 Days                     | 60 Days                     | 90 Days                    | 180 Days                   |
| <i>Corrugator supercillii</i> (n=48)                | 97.92 (6.83) <sup>A</sup>                         | 96.46 (8.63) <sup>A</sup>   | 89.58 (22.40) <sup>B</sup>  | 79.38 (33.29) <sup>C</sup> | 8.54 (19.02) <sup>D</sup>  |
| <i>Procerus</i> (n=28)                              | 98.57(5.91) <sup>A</sup>                          | 96.79 (8.63) <sup>A</sup>   | 86.43 (27.78) <sup>B</sup>  | 86.43 (27.78) <sup>B</sup> | 9.64 (20.27) <sup>C</sup>  |
| <i>Occipitofrontalis</i> (n=48)                     | 96.04 (15.67) <sup>A</sup>                        | 94.38 (16.62) <sup>AB</sup> | 88.13 (26.07) <sup>B</sup>  | 71.46 (39.68) <sup>C</sup> | 10.00 (22.41) <sup>D</sup> |
| <i>Orbicularis oculi</i><br>(n=46)                  | 95.00 (16.43) <sup>A</sup>                        | 93.91 (16.93) <sup>A</sup>  | 83.04 (31.82) <sup>B</sup>  | 70.43 (40.11) <sup>C</sup> | 10.22 (22.26) <sup>D</sup> |
| <i>Levator labii superioris</i><br>(n=15)           | 97.33 (7.99) <sup>A</sup>                         | 97.33 (7.99) <sup>A</sup>   | 88.67 (26.42) <sup>AB</sup> | 81.33 (34.82) <sup>B</sup> | 10.00 (26.46) <sup>C</sup> |
| <i>Levator labii superioris alaeque nasi</i> (n=13) | 93.85 (15.57) <sup>A</sup>                        | 91.54 (23.04) <sup>A</sup>  | 88.46 (23.04) <sup>AB</sup> | 86.15 (28.44) <sup>B</sup> | 11.54 (28.24) <sup>C</sup> |

\*Friedman test ( $P < 0.001$ ); Durbin-Conover for pairwise comparisons ( $P < 0.05$ ).

\*Values followed by different letters represent statistically significant difference ( $P < 0.05$ ).

**Table 3.** Descriptive data on the perceived efficacy of aesthetic treatment with BoNT-A in women under 40 years old and over 40 years old on follow-up days.

|  | 15 days          |                  | 30 days          |                  | 60 days          |                  | 90 days          |                  | 180 days         |                  |
|--|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Age  | <40              | >40              | <40              | >40              | <40              | >40              | <40              | >40              | <40              | >40              |
| <b>Corrugator supercillii</b>                |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| < 40 n=16; > 40 n=32                         | 98.75<br>(5.00)  | 97.50<br>(7.62)  | 97.50<br>(6.83)  | 95.94<br>(9.46)  | 88.13<br>(27.13) | 90.31<br>(20.08) | 86.25<br>(27.29) | 75.94<br>(35.82) | 18.13<br>(28.34) | 3.75<br>(9.42)   |
| <b>Procerus</b>                              |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| < 40 n=6; > 40 n=22                          | 100.00<br>(0.00) | 98.18<br>(6.65)  | 96.67<br>(8.17)  | 96.82<br>(8.94)  | 88.33<br>(20.41) | 85.91<br>(29.87) | 88.33<br>(20.41) | 85.91<br>(29.87) | 8.33<br>(13.29)  | 10.00<br>(22.04) |
| <b>Occipitofrontalis</b>                     |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| < 40 n=12; > 40 n=36                         | 98.33<br>(5.77)  | 95.28<br>(17.81) | 98.33<br>(5.77)  | 93.06<br>(18.80) | 94.17<br>(15.05) | 86.11<br>(28.71) | 80.00<br>(31.04) | 68.61<br>(42.17) | 11.67<br>(23.68) | 9.44<br>(22.29)  |
| <b>Orbicularis oculi</b>                     |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| < 40 n=13; > 40 n=33                         | 88.46<br>(28.24) | 97.58<br>(7.51)  | 88.46<br>(28.24) | 96.06<br>(9.33)  | 76.92<br>(37.50) | 85.45<br>(29.59) | 72.31<br>(36.32) | 69.70<br>(42.02) | 12.31<br>(24.21) | 9.39<br>(21.79)  |
| <b>Levator labii superiores</b>              |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| < 40 n=8; > 40 n=7                           | 96.25<br>(10.61) | 98.57<br>(3.78)  | 96.25<br>(10.61) | 98.57<br>(3.78)  | 93.75<br>(11.88) | 82.86<br>(37.29) | 80.00<br>(35.05) | 82.86<br>(37.29) | 8.75<br>(24.75)  | 11.43<br>(30.24) |
| <b>Levator labii superioris alaeque nasi</b> |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| < 40 n=9; > 40 n=4                           | 91.11<br>(8.33)  | 100<br>(0)       | 87.78<br>(27.28) | 100<br>(0)       | 85.56<br>(26.98) | 95.00<br>(10.00) | 82.22<br>(33.46) | 95.00<br>(10.00) | 7.78<br>(23.33)  | 20.00<br>(40.00) |

Student t test or Mann-Whitney test, when indicated,  $P > 0.05$

SD – Standard deviation

### “CLINICAL RELEVANCE”

This study contributes to the way of systematizing and compiling data in aesthetic treatments with BoNT-A in the muscles of facial expression, including gummy smile, demonstrating its period of effectiveness with the minimum dosage injected into the patients' muscles. Despite the effectiveness of BoNT-A being consolidated and the wide use of it, we know that its effect is not long-lasting and its duration varies, depending on the patient's metabolism, the injection protocols followed, the muscle, and the toxin reconstitution. By injecting the ideal dose of BoNT-A, for each specific muscle and period of effectiveness, it is possible to preserve the patient so that they receive a new dose only when necessary.

1  
2  
3 **“DISCLOSURE OF INTEREST”**  
4

5 The authors declare no conflicts of interest.  
6  
7  
8  
9

10 **“FUNDING DETAILS”**  
11

12 This study was partially financed by the Coordenação de Aperfeiçoamento de Pessoal de  
13 Nível Superior – Brasil (CAPES) – Finance Code 001.  
14  
15  
16  
17  
18

19 **“DATA CONFIDENTIALITY”**  
20

21 The authors declare that they followed the workplace protocols on the publication of  
22 patient data and that all participants received sufficient information and provided their  
23 written informed consent.  
24  
25  
26  
27  
28  
29

30 **“RIGHT TO PRIVACY AND INFORMED CONSENT”**  
31

32 All patients and/or subjects in this study provided a written informed consent to the  
33 authors.  
34  
35  
36

37 This document is in the possession of the correspondence author.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60